Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug935 | Clinical examination Wiki | 1.00 |
| drug3933 | Telephone follow-up Wiki | 1.00 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The Nancy Cov-H-AKI: study is a prospective, non-randomized, monocenter study performed in patients hospitalised for either the severe or the critical form of Covid-19. The main objective of the Nancy Cov-H-AKI study is to evaluate the association of variations (from inclusion to 72H post-inclusion) of 5 blood-based cardio-vascular-renal biomarkers selected a priori, cardiac (NT-proBNP), coagulation (D-dimers), related to the renin angiotensin aldosterone system (ACE2) and renal (Penkid, and NGAL) with the appearance of acute kidney injury KDIGO grade 1 or higher OR cardiac injury in patients hospitalised for either the severe or the critical form of Covid-19
Description: Composite endpoint : Worsening of renal function by at least KDIGO grade 1 criteria from inclusion visit OR troponin greater than 99th percentile during hospitalization for Covid-19 infection (with Outcome 2).
Measure: Worsening of renal function by at least KDIGO grade 1 during hospitalization for Covid-19 infection Time: From inclusion to hospital discharge, an average of 21 daysDescription: Composite endpoint : Worsening of renal function by at least KDIGO grade 1 criteria from inclusion visit OR troponin greater than 99th percentile during hospitalization for Covid-19 infection (with Outcome 1)
Measure: Troponin greater than 99th percentile during hospitalization for Covid-19 infection Time: From inclusion to hospital discharge, an average of 21 daysDescription: Composite endpoint : AKI KDIGO grade 1 or higher or Elevation of troponin> 99th percentile in hospitalisation (approach with AND without a priori) ((with Outcome 3 )
Measure: AKI KDIGO grade 1 or higher in hospitalisation (approach with AND without a priori) Time: From inclusion to hospital discharge, an average of 21 daysDescription: Composite endpoint : AKI KDIGO grade 1 or higher or Elevation of troponin> 99th percentile in hospitalisation (approach with AND without a priori) (with Outcome 3)
Measure: Elevation of troponin> 99th percentile in hospitalisation (approach with AND without a priori) Time: From inclusion to hospital discharge, an average of 21 daysDescription: AKI KDIGO grade 1 in hospitalisation
Measure: AKI KDIGO grade 1 or higher Time: From inclusion to hospital discharge, an average of 21 daysDescription: Association with troponin elevation >99th percentile during hospitalisation
Measure: Association with troponin elevation >99th Time: From inclusion to hospital discharge, an average of 21 daysDescription: Association with elevation of serum creatinine >30% during hospitalisation
Measure: Association with elevation of serum creatinine >30% Time: From inclusion to hospital discharge, an average of 21 daysDescription: With the onset of chronic renal failure (eDFG <60 ml / min / 1.73m2) three months after discharge from hospital
Measure: With the onset of chronic renal failure (eDFG <60 ml / min / 1.73m2) Time: 3 months after discharge from hospitalDescription: Composite outcome : the occurrence of cardiovascular events (stroke, myocardial infarction, hospitalisation for heart failure, cardiovascular death) and death from any cause during hospitalisation and three months after discharge from hospital
Measure: The occurrence of cardiovascular events (stroke, myocardial infarction, hospitalisation for heart failure, cardiovascular death) during hospitalisation and three months after discharge from hospital Time: From inclusion to three months after discharge from hospitalDescription: Composite outcome : the occurrence of cardiovascular events (stroke, myocardial infarction, hospitalisation for heart failure, cardiovascular death) and death from any cause during hospitalisation and three months after discharge from hospital
Measure: The occurrence of death from any cause during hospitalisation and three months after discharge from hospital Time: From inclusion to three months after discharge from hospitalAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports